EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
NCT ID: NCT06392828
Last Updated: 2024-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
112 participants
OBSERVATIONAL
2024-04-15
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Preliminary epidemiological studies suggested that the fat infiltration in the liver mirrored the cardiometabolic status of the patient. But recent studies postulate that NAFLD could be a potential independent predictor of vascular injury.
The mechanisms that link liver function and endothelial damage include modulation of adipose tissue function, lipid metabolism regulation or glycemic homeostasis, among others. But new mechanisms that could link NAFLD and ECV are emerging. The synthesis of ketone bodies in the liver is closely related to the cardiovascular system function. Ketone bodies can provide up to 50% of energy required by specific tissues. Plasma concentration of β-hydroxybutyrate is a biomarker of NAFLD. Plasma β-hydroxybutyrate and acetoacetate levels are also inversely associated with endothelial injury.
Other biomarkers on endothelial damage like von Willebrand factor, ICAM, VCAM or coagulation factors (Factor VIII) can be used to stratify patients according to the risk of CVD. The improvement in the sensitivity, specificity and accuracy of scores such as FLI, HIS and FIB-4 and non-invasive techniques such as elastography allow the study of the relationship between liver disease and other comorbidities.
The aim is to evaluate the potential of NAFLD to stratify patients according to the risk of CVD and to investigate the molecular mechanisms linking NAFLD and CVD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
NCT03534908
NAFLD Among Patients With Type 2 Diabetes and CKD
NCT03826381
Characteristics of NAFLD Among Type 2 Diabetes Patients
NCT04999124
Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions
NCT06932289
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
NCT02520609
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The specific objectives are:
O1) To define the association between NAFLD prevalence and degree and endothelial damage.
The investigators will use non-invasive methods to determine the presence and degree of NAFLD (FLI, echography, elastography, FIB-4, NAFLD score and Hepamet) and the investigators will compare plasma concentrations of endothelial damage biomarkers (Von Willebrand Factor, Factor VIII and Tissue Factor) among NAFLD degrees.
O2) To describe the role of hepatic ketogenic metabolism as mediator of endothelial damage.
The investigators will correlate plasma concentrations of β-hydroxybutyrate and keto acetone with plasma concentrations of biomarkers of endothelial damage.
O3) To compare the expression of genes and microRNAs involved in endothelial function and liver metabolism and inflammation biomarkers among groups.
Liver metabolism is strictly regulated through the regulation of the expression of genes encoding metabolic enzymes responsible for the metabolic reactions and transporters of intermediate metabolites. The expression of such genes also depends on epigenetic mechanisms like microRNAs. Thus, the investigators will compare the expression of a selected panel of genes and microRNAs in blood samples of participants according to the clinicopathological group. The investigators will measure circulating microRNAs in plasma and cellular genes and microRNAs in the cellular fraction of the blood samples.
O4) To determine the role of the microbiome as mediator of the link between NAFLD and CVD.
The investigators will collect fecal samples from participants, and the investigators will compare alpha diversity and composition of the gut microbiota of the volunteers of the different clinicopathological groups. The investigators will also carry out comparative metagenomic studies.
Objectives 1 to 4 will be developed through a cross-sectional study in the participants.
O5) To associate NAFLD with the incidence of CVD events or changes in endothelial damage biomarkers.
Recruited participants with or without prevalent CVD will be followed up for 5 years to evaluate if the prevalence of NAFLD is associated with the incidence of CVD major events (cardiovascular mortality, myocardial infarction, stroke or chest angina).
To develop this aim, the investigators will carry out a longitudinal cohort study for 5 years. Participants recruited in any of the 4 clinicopathological groups will be contacted annually for 5 years to collect clinical, lifestyle and anthropometrical data. They will be also submitted to usual care protocols for their pathologies. Clinical records will be checked to assess the incidence of CVD events.
The aim is to recruit 112 participants, men and women, 50-69 years old that will be segregated according to NAFLD and CVD status:
Group 1: no NAFLD, no prevalent CVD. Group 2: NAFLD, no prevalent CVD Group 3: no NAFLD, prevalent CVD Group 4: NAFLD, prevalent CVD No NAFLD is described as Fatty Liver Index (FLI) \<30 or hepatic echography negative for liver steatosis if FLI \>30 or FLI \< 60, con SCORE2 \< 5 %.
NAFLD is described as FLI \> 60 or hepatic echography positive for liver steatosis if FLA\>30 or FLI \< 60, con SCORE2 \> 5 %.
Prevalent CVD is defined according to ESC 2011 guidelines (chest angina, stroke, acute coronary syndrome or acute myocardial infarction).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: no NAFLD, no prevalent CVD.
The aim of this group is to serve as control group. FLI \<30 or hepatic echography negative for liver steatosis if FLI \>30; FLI \< 60, con SCORE2 \< 5 % and no prevalent CVD according to ESC 202122.
No interventions assigned to this group
Group 2: NAFLD, no prevalent CVD
FLI \>60 or hepatic echography positive for liver steatosis if FLI \>30; FLI \< 60, con SCORE2 \> 5 % and no prevalent CVD according to ESC 202122.
No interventions assigned to this group
Group 3: no NAFLD, prevalent CVD
FLI \<30 or hepatic echography negative for liver steatosis if FLI \>30; FLI \< 60, con SCORE2 \< 5 % and prevalent CVD (chest angina, stroke, acute coronary syndrome, accute myocardial infarction).
No interventions assigned to this group
Group 4: NAFLD, prevalent CVD
FLI \>60 or hepatic echography positive for liver steatosis if FLI \>30; FLI \< 60, con SCORE2 \> 5 % and prevalent CVD (chest angina, stroke, acute coronary syndrome, accute myocardial infarction).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 50-69 years old
* With CVD stratification according to ESC 2011 guidelines.
* With data to calculate NAFLD scores.
Exclusion Criteria
* Taking hypoglycemic drugs.
* Familiar hypercholesterolemia according to ESC criteria.
* Congenital defects on lipid metabolism.
* Taking hypolipidemic drugs targeting PCSK9.
* Participating on other clinical trials.
* Chronic renal disease with filtration rate \< 30 ml/min (RCD degree 4 KDIGO).
* Active cancer
* Liver disease no NAFLD.
* Von Willebrand disease or any other genetic condition with an impact on the plasma concentration of this biomarker.
* Systemic autoimmune disease.
* Uncapable of giving informed consent.
* Any other physical or cognitive condition that could affect the participation in the study.
50 Years
69 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sociedad Española de Arteriosclerosis
OTHER
Clinica Universidad de Navarra, Universidad de Navarra
OTHER
Hospital HM Montepríncipe
UNKNOWN
Hospital Central de la Defensa Gómez Ulla
OTHER
Hospital Universitario 12 de Octubre
OTHER
IMDEA Food
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lidia Daimiel Ruiz
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lidia Daimiel Ruiz, PhD
Role: PRINCIPAL_INVESTIGATOR
Fundación IMDEA Alimentación
Diego Martínez Urbistondo, PhD
Role: STUDY_CHAIR
Clínica Universidad de Navarra
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clínica Universidad de Navarra
Madrid, , Spain
Hospital 12 de Octubre
Madrid, , Spain
Hospital Central de la Defensa Gomez Ulla
Madrid, , Spain
Hospital HM Montepríncipe
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PI-058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.